Proliferative Vitreoretinopathy Clinical Trial
Official title:
Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Retinal Detachment With Proliferative Vitreoretinopathy Using 3D Visualization System
The aim of this study is to report outcomes of pars plana vitrectomy (PPV) in retinal
detachment (RD) accompanied with proliferative vitreoretinopathy (PVR) after extensive
Brilliant Blue G-Assisted internal limiting membrane (ILM) peeling using a 3D visualization
system.
This is retrospective consecutive case series of 14 eyes treated with PPV for RD repair. The
patients were follow for 7 to 47 months (mean follow-up: 14.1 months ).
This is the retrospective study of 14 consecutive patients suffering from retinal detachment
with proliferative vitreoretinopathy who underwent primary PPV at the Department of Retina of
Centro Oftalmologico Dr Charles, Buenos Aires-Argentina between January 1, 2016 and August 1,
2020 . This study followed the tenets of the Declaration of Helsinki and it was approved by
the approved by the research ethics committee (www.comitedeeticaceic.com.ar). Written
informed consent was taken from all subjects. All cases were performed by a single
experienced vitreoretinal surgeon (MCH)
The treatment chosen in the study was pars plana vitrectomy with Brilliant Blue G (BBG)
staining using the Ngenuity 3D Visualization System (Alcon). We spread 0.05% w/v BBG solution
(OCUBLUE PLUS, Aurolab), approximately 0.3-0.5 ml, on the retinal surface and peeled off the
ILM from the posterior pole up to the periphery, thus ensuring the total removal of the
overlying epiretinal membranes responsible for recurrent detachment. Frequent restaining with
BBG helped revealing new edges and perfluorocarbon liquid was used in others to stabilize the
retina (Figure1). ).. All patients underwent vitreoretinal surgery due to RD (rhegmatogenous,
tractional or combined rhegmatogenous and tractional). Exclusion criteria from the study was
the time of follow-up less than 6 months.
Average age at the time of the presence of RD was 56 ± 8.7 years (range 23-77 years). Pre-
and postoperative data were collected. Descriptive statistical analysis included gender, age
at the presentation, laterality, etiology, duration of presenting symptoms, presences of
ocular comorbidities, macular status (attached or non-attached), presence of PVR (preretinal,
subretinal and intraretinal) initial and final best-corrected visual acuity (BCVA), number of
procedures, type of endotamponade during PPV, final lens status, duration of the follow-up,
anatomical success and complications. Indications for PPV were as follows: presence of
advanced PVR and/or total RD and/or multiple breaks, giant retinal tears. PVR was graded
according to the Retina Society Terminology Classification and anatomical location
(references). Visual acuity was measured by Snellen charts. The anatomical success was
defined as persistent retinal reattachment at the last follow-up visit (in absence of
silicone oil tamponade).
Statistical computations were performed using STATA 16 data analysis and statistical software
(StataCorp LLC, College Station, Texas, USA)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561569 -
Air Versus Gas Tamponade in Primary Retinal Detachment
|
N/A | |
Not yet recruiting |
NCT05538156 -
Internal Limiting Membrane Peeling in Retinal Detachment Surgery
|
N/A | |
Completed |
NCT01445028 -
Isotretinoin for Proliferative Vitreoretinopathy
|
Phase 4 | |
Recruiting |
NCT00370760 -
Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR)
|
Phase 3 | |
Completed |
NCT00000140 -
The Silicone Study
|
Phase 3 | |
Completed |
NCT06166914 -
Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment
|
N/A | |
Recruiting |
NCT04580147 -
Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair
|
Phase 2 | |
Completed |
NCT04891991 -
Intravitreal Infliximab for Proliferative Vitreoretinopathy
|
Phase 2 | |
Completed |
NCT01255293 -
Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments
|
N/A | |
Completed |
NCT04136366 -
The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy
|
Phase 3 | |
Recruiting |
NCT06289205 -
"Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy"
|
Phase 1/Phase 2 | |
Completed |
NCT00373282 -
Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy
|
Phase 3 | |
Completed |
NCT01995045 -
Postoperative Pain Control Following Vitreoretinal Surgery
|
Phase 4 | |
Not yet recruiting |
NCT06425419 -
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
|
Phase 1 | |
Completed |
NCT02192970 -
Bevacizumab Against Recurrent Retinal Detachment
|
Phase 2 | |
Not yet recruiting |
NCT04682054 -
Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics
|
N/A | |
Recruiting |
NCT05660447 -
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06033703 -
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00371020 -
The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR
|
Phase 3 | |
Completed |
NCT03727776 -
Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)
|
Early Phase 1 |